Datapoint: Pfizer Seeks Full Approval for Paxlovid

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 7

Pfizer last week announced it has asked the FDA for full standard approval of its COVID-19 antiviral, Paxlovid, in patients at risk of developing severe illness from the virus. Paxlovid is currently Pfizer’s No. 2 best-selling drug, according to data from Evaluate Pharma. Evaluate projects total Paxlovid sales of $29.4 billion in 2022, dropping to $14.8 billion in 2023.

From Evaluate Pharma

0
0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 23

Datapoint: Elevance to Take On Primary Care Expansion

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 18

Datapoint: FDA Delays New Leqembi Launch

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 17

Datapoint: Clover Health to Settle Shareholder Lawsuits

Read More

The Latest

enhance-patient-assistance-programs

Meet Our Reporters

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today